Eiletoclax - Eilean Therapeutics
Alternative Names: ZE-500134Latest Information Update: 29 Jan 2025
At a glance
- Originator Eilean Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Chronic lymphocytic leukaemia
Most Recent Events
- 21 May 2024 Eilean Therapeutics initiates a phase I trial (In volunteers) in Australia (PO) (NCT06787131)
- 09 Dec 2023 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Acute myeloid leukaemia and Chronic lymphocytic leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 31 Oct 2023 Phase-I clinical trials in Acute myeloid leukaemia (unspecified route) (before October 2023) (Eilean Therapeutics pipeline, October 2023)